Feedback / Questions
levodopa/carbidopa low dose (ND0612L) - Mitsubishi Tanabe
levodopa/carbidopa high dose (ND0612H) - Mitsubishi Tanabe
ND0612: Approval for moderate/severe Parkinson's disease in FY 2019
(Mitsubishi Tanabe)
-
Jan 18, 2018 -
Business Briefing
Regulatory
•
CNS Disorders • Parkinson's Disease
https://www.mt-pharma.co.jp/e/ir/meeting/pdf/e_presen171205_M.pdf
Jan 18, 2018
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious